Back to Agendas
Breakthrough Medicines or Affordable Health Care: Do We Have to Choose?
Session Chair(s)
Kenneth I. Kaitin, PhD
Professor and Senior Fellow, Tufts Center for the Study of Drug Development, United States
A recent study by the Tufts Center for the Study of Drug Development reported that it cost $2.6 billion to bring a new medicine to market, more than double the cost of a decade ago. This high cost of development highlights the importance for drug sponsors to generate an adequate rate of return on their investment. However, as overall health care costs continue to rise, pharmaceutical companies are under increasing pressure to demonstrate the economic value of their products and justify prices. In this forum, panelists will explore the potentially competing demands for innovative breakthrough medicines and health care cost containment, and will examine regulatory initiatives and new business practices geared toward boosting innovation while lowering treatment costs.
Learning Objective : Describe the competing demands for innovative breakthrough medicines and health care cost containment; Discuss regulatory initiatives and new business practices geared toward boosting innovation while lowering treatment costs.
Speaker(s)
Panelist
Hans-Georg Eichler, MD, MSc
Consulting Physician, Austrian Association of Social Security Bodies, Austria
Panelist
Ellen Sigal, PhD
Chairperson and Founder, Friends of Cancer Research, United States
Panelist
Margaret A. Anderson, MA
Executive Director, FasterCures, A Center of the Milken Institute, United States
Panelist
Charles A. Stevens, JD, MBA
Vice President and General Manager, PAREXEL Consulting, United States
Panelist
David Vulcano, MBA, RAC
CEO, ACRP | Association of Clinical Research Professionals, United States
Have an account?